TransMedics Group Inc. (TMDX)
TransMedics Group Statistics
Share Statistics
TransMedics Group has 33.56M shares outstanding. The number of shares has increased by 2.59% in one year.
| Shares Outstanding | 33.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.61% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.43M |
| Failed to Deliver (FTD) Shares | 1.85K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 8.64M, so 25.74% of the outstanding shares have been sold short.
| Short Interest | 8.64M |
| Short % of Shares Out | 25.74% |
| Short % of Float | 26.64% |
| Short Ratio (days to cover) | 4.5 |
Valuation Ratios
The PE ratio is -102.55 and the forward PE ratio is 58.62.
| PE Ratio | -102.55 |
| Forward PE | 58.62 |
| PS Ratio | 10.62 |
| Forward PS | 3.2 |
| PB Ratio | 18.71 |
| P/FCF Ratio | -13.36 |
| PEG Ratio | n/a |
Enterprise Valuation
TransMedics Group Inc. has an Enterprise Value (EV) of 2.69B.
| EV / Earnings | -107.39 |
| EV / Sales | 11.12 |
| EV / EBITDA | -353.51 |
| EV / EBIT | -93.56 |
| EV / FCF | -13.99 |
Financial Position
The company has a current ratio of 9.3, with a Debt / Equity ratio of 3.76.
| Current Ratio | 9.3 |
| Quick Ratio | 8.49 |
| Debt / Equity | 3.76 |
| Total Debt / Capitalization | 78.99 |
| Cash Flow / Debt | -0.03 |
| Interest Coverage | -2.66 |
Financial Efficiency
Return on equity (ROE) is -0.18% and return on capital (ROIC) is -4.13%.
| Return on Equity (ROE) | -0.18% |
| Return on Assets (ROA) | -0.04% |
| Return on Capital (ROIC) | -4.13% |
| Revenue Per Employee | 413.74K |
| Profits Per Employee | -42.86K |
| Employee Count | 584 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | -1.64M |
| Effective Tax Rate | 0.06 |
Stock Price Statistics
The stock price has increased by -31.18% in the last 52 weeks. The beta is 2.07, so TransMedics Group 's price volatility has been higher than the market average.
| Beta | 2.07 |
| 52-Week Price Change | -31.18% |
| 50-Day Moving Average | 70.07 |
| 200-Day Moving Average | 119.23 |
| Relative Strength Index (RSI) | 43.07 |
| Average Volume (20 Days) | 2.34M |
Income Statement
In the last 12 months, TransMedics Group had revenue of 241.62M and earned -25.03M in profits. Earnings per share was -0.77.
| Revenue | 241.62M |
| Gross Profit | 154.09M |
| Operating Income | -28.73M |
| Net Income | -25.03M |
| EBITDA | -7.60M |
| EBIT | -28.73M |
| Earnings Per Share (EPS) | -0.77 |
Balance Sheet
The company has 394.81M in cash and 515.95M in debt, giving a net cash position of -121.13M.
| Cash & Cash Equivalents | 394.81M |
| Total Debt | 515.95M |
| Net Cash | -121.13M |
| Retained Earnings | -503.70M |
| Total Assets | 785.57M |
| Working Capital | 432.43M |
Cash Flow
In the last 12 months, operating cash flow was -13.03M and capital expenditures -179.06M, giving a free cash flow of -192.09M.
| Operating Cash Flow | -13.03M |
| Capital Expenditures | -179.06M |
| Free Cash Flow | -192.09M |
| FCF Per Share | -5.91 |
Margins
Gross margin is 63.77%, with operating and profit margins of -11.89% and -10.36%.
| Gross Margin | 63.77% |
| Operating Margin | -11.89% |
| Pretax Margin | -11.04% |
| Profit Margin | -10.36% |
| EBITDA Margin | -3.15% |
| EBIT Margin | -11.89% |
| FCF Margin | -79.5% |
Dividends & Yields
TMDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.26% |
| FCF Yield | -9.38% |
Analyst Forecast
The average price target for TMDX is $120, which is 96.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $120 |
| Price Target Difference | 96.6% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 2.6 |
| Piotroski F-Score | 5 |